Overview
Elixirgen Therapeutics develops cell and gene therapies for rare diseases and aging-associated conditions using proprietary ZSCAN4 technology for telomere extension and mRNA platforms like Bobcat mRNA and controllable self-replicating RNA. Their lead candidate EXG-34217, an autologous cell therapy for telomere biology disorders, has FDA RMAT designation and positive Phase I/II data showing sustained telomere elongation. The company also advances RNA vaccine technologies and large protein delivery for applications in muscular dystrophy and infectious diseases.
Frequently asked questions
- What is Elixirgen Therapeutics' core technology?
- Proprietary ZSCAN4 technology enables telomerase-independent telomere extension to restore stem cell potency, used in EXG-34217 for telomere biology disorders.
- What is the clinical status of EXG-34217?
- Phase I/II trial (NCT04211714) ongoing at Cincinnati Children’s, with early data showing sustained telomere elongation in patients and FDA RMAT designation.
- What mRNA platforms does Elixirgen offer?
- Bobcat mRNA for large proteins like full-length dystrophin, controllable self-replicating RNA (c-srRNA) with temperature regulation, and ZSCAN4 via RNA virus for genetic therapies.